No FDA approval for Rejuran, PN, or PDRN injectable skin boosters was identified in the sources reviewed on September 18, 2026. A topical cosmetic is not an approved injectable, and an unapproved imported product is not simply an approved drug used off-label. Ask for the exact product, route, and FDA record before treatment.
United States Status: Checked September 18, 2026
No FDA approval for a Rejuran, PN, or PDRN injectable skin booster was identified in the FDA sources reviewed for this article. Do not treat availability at a clinic, overseas authorization, or a seller’s “FDA registered” claim as proof of US approval. Ask for the exact product and the FDA approval or clearance record covering its intended use.
Topical products are a separate category. Cosmetics generally do not require FDA premarket approval, except for certain color additives, but they must comply with safety and labeling requirements. A product’s ingredients, claims, and intended use determine how it is regulated. The presence of PDRN does not make every formulation lawful or FDA approved. See the FDA’s explanation of cosmetic regulation.
How to verify current FDA status: Search the product name in the FDA’s medical device database or the FDA Drugs@FDA database. Match the manufacturer, formulation, route, and intended use to the record. Registration or listing alone is not approval. Regulatory status can change; ask the clinician for the specific approval or clearance number rather than relying on advertising.
What PDRN, PN, and Rejuran Mean
PDRN stands for polydeoxyribonucleotide, a mixture of DNA fragments used in some products marketed for skin repair.
PN means polynucleotide. In aesthetic products, it commonly describes longer DNA chains. PN and PDRN labels do not establish that different formulations have equivalent composition or clinical effects.
Rejuran is a brand associated with salmon-derived PN products. A brand can include different formulations and routes of use; a topical product should not be confused with an injectable.
“Salmon DNA” is marketing shorthand, not a standardized treatment. Product source, processing, concentration, other ingredients, and administration route matter. Similarity between DNA building blocks does not rule out allergic reactions or establish that a product is safe.
Topical Products Compared With Injections
A cream on intact skin and an intradermal injection are not interchangeable. Evidence for one route or formulation cannot automatically be applied to another.
| Factor | Injectable PN / PDRN (e.g. Rejuran) | Topical PDRN serum or cream |
|---|---|---|
| Route | Intradermal injection by a clinician | Applied to skin surface |
| Purpose | Marketed for skin-quality concerns; benefit is product- and study-specific | Surface conditioning or moisturization, depending on the full formula |
| US status | No US approval identified in reviewed sources | Cosmetic rules apply; not FDA approved |
| Evidence | Small clinical trials; limited long-term and comparative evidence | Injectable findings do not establish topical efficacy; assess the specific formula |
| Cost | No verified US price range provided; a quote does not establish approval | Varies by brand, size, and formulation; check current retailer pricing |
| Availability | Clinic availability is not evidence of FDA approval or lawful marketing | Sold by retailers; verify labeling and intended topical use |
| Downtime | Pain, redness, swelling or bruising may occur; recovery and complications vary | Irritation or allergic reactions can occur |
FDA Approval Is Not the Same as Off-Label Use
The FDA describes off-label drug use as use of an already approved drug in a way that differs from its approved labeling, such as a different condition, dose, or route. An imported injectable that has no US approval should not simply be described as an approved product used “off-label.” See FDA guidance on off-label use.
A clinic advertisement is not evidence that a product has a lawful US marketing pathway. Importation, investigational use, and compounding have separate requirements; a general discussion cannot establish the legality of an individual clinic’s practice. Request verifiable product documentation before considering treatment.
What this means for patients:
- Ask for the exact product name, manufacturer, lot number, storage conditions, and FDA record.
- Do not equate foreign authorization, facility registration, or a marketing claim with US approval for injection.
- Ask who handles complications and what follow-up is available.
- Adverse events can be reported through FDA MedWatch; seek clinical care first when symptoms are urgent.
Evidence and Expected Results
Early clinical findings are promising, but they do not establish that all PN or PDRN products work equally well or are safe over the long term.
What a controlled trial found
A randomized, double-blind, split-face trial by Lee and colleagues studied 27 people receiving PN on one side of the eye area and non-crosslinked hyaluronic acid on the other. Both sides improved on global aesthetic assessments, without a significant between-treatment difference on those assessments. Some instrument-measured outcomes favored PN. This small, product-specific trial does not establish superiority for every cosmetic goal or detect uncommon harms.
What remains uncertain
Long-term safety and the frequency of uncommon complications.
Which formulation, treatment schedule, and patient groups benefit most.
Whether findings for one injectable apply to another product or to a topical serum.
Whether proposed biological mechanisms translate into meaningful visible improvement for a particular patient.
Do not assume that an injectable trial proves a cream stimulates collagen or repairs deeper tissue. A topical moisturizer’s benefits may come from the overall formulation, not necessarily PDRN itself.
Risks and Questions to Discuss With a Clinician
Small studies reporting few serious events are not a guarantee of safety. Injections can cause pain, swelling, bruising, infection, and inflammatory or allergic reactions; the risks also depend on product quality, anatomy, and technique. Do not assume all reactions resolve within a fixed number of days.
Disclose fish allergy and any previous reaction to injectable or skin-care ingredients; review the specific product’s composition and labeling.
Discuss active skin infection, pregnancy or breastfeeding, autoimmune disease, immune-suppressing treatment, and all medicines with the clinician. These require individual assessment, not a universal rule for every formulation.
Ask how authenticity, lot number, storage, sterility, and complication management are verified.
Do not inject or microneedle a topical cosmetic into your skin yourself.
Seek urgent medical assessment for severe or increasing pain, spreading redness, skin discoloration, or visual symptoms after an injection. Difficulty breathing or another emergency requires emergency care.
Alternatives: Check the Specific FDA-Labeled Use
Other treatments may address smoothness, lines, texture, or volume through different mechanisms. They are not equivalent substitutes for every goal. Approval or device clearance applies to a particular product and indication—not to an entire category or every combination treatment.
SKINVIVE by Juvéderm
An HA gel approved for cheek skin smoothness in adults over 21. The June 11, 2026 supplement also covers correction of neck lines in adults over 21. It is not PDRN; candidacy, contraindications, and risks require review.
Read current FDA indication →PRP and PRF
These use blood-derived preparations. Clearance of a preparation device does not establish FDA approval of PRP or PRF for facial rejuvenation. Ask about the specific procedure’s evidence, risks, and device labeling.
Microneedling
Some devices are cleared for specific skin concerns. The FDA has not approved microneedling devices to deliver cosmetics, drugs, or blood products such as PRP into skin. Clearance of the device does not mean a PRP or PDRN combination is approved.
FDA microneedling guidance →Dermal Fillers
Selected fillers have FDA-approved indications for particular areas or concerns. They are not risk-free or interchangeable, and “reversible” should not be read as a guarantee that every complication can be reversed.
Explore dermal fillers →Frequently Asked Questions
-
No FDA approval for Rejuran as an injectable skin booster was identified in the sources reviewed on September 18, 2026. Overseas authorization, a clinic offering treatment, or an FDA registration claim is not proof of US approval. Ask for the exact product and its FDA record.
-
An unapproved imported injectable is not simply an FDA-approved product used off-label. No US approval for a PN or PDRN injectable skin booster was identified in the sources reviewed. Importation, investigational use, and compounding have separate requirements; legality cannot be established from a clinic advertisement. Request product-specific documentation.
-
A topical formula may moisturize or condition skin, but an injectable study does not prove that a cream has the same effects. Evaluate evidence for the exact formulation and route. Cosmetic availability is not FDA approval, and benefits cannot automatically be attributed to PDRN rather than other ingredients.
-
PDRN means polydeoxyribonucleotide, a mixture of DNA fragments. PN means polynucleotide and commonly describes longer chains in aesthetic products. Product source, concentration, processing, and other ingredients vary. The names do not establish that products are interchangeable or equally effective.
-
There is no verified US price range provided here. A clinic quote does not establish regulatory approval. Ask for the exact product, treatment area, number of visits, and total cost, including follow-up. Topical prices vary by formulation, size, and retailer.
-
SKINVIVE has specific FDA-approved indications for cheek smoothness and, under a June 2026 supplement, neck lines in adults over 21. Selected fillers and microneedling devices have their own indications. PRP or PRF preparation-device clearance does not equal approval for facial rejuvenation, and FDA has not approved microneedling devices to deliver PRP or cosmetics into skin.
Dr. Kim’s Video Discussion
The video below provides additional background. Regulatory information can change after recording; use the dated FDA sources and distinctions in this article when checking current product status.
Questions to Ask Before Choosing a Treatment
What is the exact product name, manufacturer, and route of administration?
Can you show the FDA record and approved or cleared indication?
What published study supports this specific product for my goal?
What are the risks, alternatives, expected recovery, and total quoted cost?
Who treats complications and how do I reach them?
Contact Dr. Kim’s office to discuss your goals and confirm which treatments are currently offered. Read about dermal fillers and Roy Kim, MD’s training and experience.
Sources and Editorial Review
Sources checked September 18, 2026: FDA off-label guidance; FDA cosmetic regulation; FDA microneedling guidance; SKINVIVE approval supplement, June 11, 2026; and Lee et al., randomized PN-versus-HA trial. This editorial update is pending physician review and is not individualized medical or legal advice.